soul trial oral semaglutide cardiovascular outcomes soul trial results The (Semaglutide Trial) was a randomized, double-blind, placebo-controlled cardiovascular outcomes that enrolled 9,650 patients aged 50 years or older with soul trial oral semaglutide cardiovascular
Description
Increased injection frequency risks Each subcutaneous injection carries a small risk of infection, bruising, and tissue damage
Food and Drug Administration (FDA) for multiple conditions, including major adverse cardiac events, metabolic-associated steatohepatitis, and sleep apnea, while other conditions are being reviewed
"We are excited to collaborate with Hansoh Pharma on HS-10270 , an investigational oral GLP-1 receptor agonist that has the potential to offer patients a convenient and effective treatment option for managing type 2 diabetes and obesity," said Dr
2019, p
